### ICB_Wolf2

- **Read Paper:** [Durvalumab with Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results from the Adaptively Randomized I-SPY2 Platform Trial](https://pubmed.ncbi.nlm.nih.gov/34143979) (PMID: 34143979)
- **Data Availability:**
  - **Number of Patients:** 105
  - **Access:** Available at GEO
  - **Accession Number:** [GSE173839](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE173839)
    - **Microarray Data:**
      - [Expression Data (Agilent 44K, Mean Column)](https://ftp.ncbi.nlm.nih.gov/geo/series/GSE173839/GSE173839_ISPY2_AgilentGeneExp_durvaPlusCtr_FFPE_meanCol_geneLevel_n105.txt.gz)
      - [Expression Data (Agilent 44K, Probe Level)](https://ftp.ncbi.nlm.nih.gov/geo/series/GSE173839/GSE173839_ISPY2_AgilentGeneExp_durvaPlusCtr_FFPE_probeLevel_n105.txt.gz)
      - [Biomarker Data](https://ftp.ncbi.nlm.nih.gov/geo/series/GSE173839/GSE173839_ISPY2_DurvalumabOlaparibArm_biomarkers.csv.gz)

